| Pharmaceutical Information |
| Drug Name |
Etelcalcetide |
| Drug ID |
BADD_D02514 |
| Description |
Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. |
| Indications and Usage |
Etelcalcetide is a calcium-sensing receptor agonist indicated for:
Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. |
| Marketing Status |
approved; investigational |
| ATC Code |
H05BX04 |
| DrugBank ID |
DB12865
|
| KEGG ID |
D10676
|
| MeSH ID |
C583569
|
| PubChem ID |
71511839
|
| TTD Drug ID |
D07RYI
|
| NDC Product Code |
55463-0030; 55513-741; 55513-740; 52076-6227; 55513-742 |
| UNII |
60ME133FJB
|
| Synonyms |
etelcalcetide hydrochloride | velcalcetide | etelcalcetide | KAI-4169 | Parsabiv | AMG-416 | AMG 416 |
|
| Chemical Information |
| Molecular Formula |
C38H73N21O10S2 |
| CAS Registry Number |
1262780-97-1 |
| SMILES |
CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=
C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
|
|
|
